Bladder Cancer Clinical Trials 2022

Browse 200 Bladder Cancer Medical Studies Across 498 Cities
29 Phase 3 Trial · 2669 Bladder Cancer Clinics

Display Results

All

Most EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Bladder Cancer Clinical Trials 2022

Reviewed by Michael Gill, B. Sc.

Image of University of Colorado Cancer Center in Aurora, United States.

Phase-Based Progress Estimates

BT5528for Advanced Solid Tumor Identified as Positive for EphA2 Tumor Expression by Central Laboratory (Phase 1)

This trial is testing a drug called BT5528 to see if it is safe and effective for treating various types of cancer.

Phase 1 & 2

Recruiting

FDA Approved Drug

California Cancer Associates for Research and Excellence, Inc. (+14 Sites)Hendrik-Tobias Arkenau, MD, PhDBicycleTx Limited

Image of USC Institute of Urology in Los Angeles, United States.

Phase-Based Progress Estimates

Erdafitinibfor Urinary Bladder Cancer

This trial will compare recurrence-free survival rates for patients with high-risk bladder cancer who have FGFR mutations or fusions and have had a recurrence after BCG therapy, between those who receive erdafitinib and those who receive the investigator's choice of standard therapy.

Phase 2

Recruiting

FDA Approved Drug

USC Institute of Urology (+14 Sites)Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC

Image of Local Institution in Levis, Canada.

Phase-Based Progress Estimates

Nivolumabfor Urinary Bladder Cancer

This trial compares nivolumab, a drug that helps the body's immune system, with bacterial drugs alone in people with high risk bladder cancer.

Phase 3

Waitlist Available

FDA Approved Drug

Local Institution (+1 Sites)Bristol-Myers SquibbBristol-Myers Squibb

Image of Arizona Oncology Associates in Tucson, United States.

Phase-Based Progress Estimates

BMS-986205for Urinary Bladder Cancer

This trial will compare the efficacy of nivolumab plus neoadjuvant gemcitabine/cisplatin chemotherapy followed by post-surgery continuation of immuno-oncology therapy versus neoadjuvant gemcitabine/cisplatin chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer.

Phase 3

Recruiting

FDA Approved Drug

Arizona Oncology Associates (+26 Sites)Bristol-Myers SquibbOno Pharmaceutical Co. Ltd

Image of Research Site in Birmingham, United States.

Phase-Based Progress Estimates

Olaparibfor Urinary Bladder Cancer

This trial is testing a combination of two drugs, durvalumab and olaparib, to see if it is effective and safe in treating patients with urothelial cancer that has spread and cannot be removed by surgery.

Phase 2

Waitlist Available

FDA Approved Drug

Research Site (+17 Sites)Jonathan Rosenberg, MDAstraZeneca

Image of Banner MD Anderson Cancer Center in Gilbert, United States.

Phase-Based Progress Estimates

Enfortumab Vedotin (EV)for Cancer of Ureter

This trial will test an experimental drug, enfortumab vedotin, either alone or in combination with other cancer treatments. Pembrolizumab is a checkpoint inhibitor that is used to treat patients with urothelial cancer--a type of cancer that includes bladder, renal pelvis, ureter, or urethra cancer. The study will examine the side effects of enfortumab vedotin and measure if the cancer shrinks with different treatment combinations.

Phase 1 & 2

Recruiting

FDA Approved Drug

Banner MD Anderson Cancer Center (+84 Sites)Anne-Sophie Carret, MDAstellas Pharma Global Development, Inc.

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Phase-Based Progress Estimates

Vicineumfor Urinary Bladder Cancer

This trial is testing if the drugs Durvalumab and Vicineum together are safe and effective to treat people with bladder cancer that has not spread to the muscle in the bladder.

Phase 1

Recruiting

FDA Approved Drug

National Institutes of Health Clinical CenterVladimir A Valera Romero, M.D.

Image of Alaska Urological Institute in Anchorage, United States.

Phase-Based Progress Estimates

Enfortumab Vedotinfor Urologic Neoplasms

This trial will test the experimental drug enfortumab vedotin on patients with urothelial cancer who have been previously treated with an immune checkpoint inhibitor. The study will look at if the cancer shrinks with treatment and also the side effects of the drug.

Phase 2

Waitlist Available

FDA Approved Drug

Alaska Urological Institute (+65 Sites)Janet Trowbridge, MD, PhDAstellas Pharma Global Development, Inc.

Image of University of Alabama At Birmingham in Birmingham, United States.

Phase-Based Progress Estimates

Atezolizumabfor Urinary Bladder Cancer

This trial is testing a new cancer treatment for people with bladder cancer that has spread or come back after other treatments. The drug is given through an IV, and people are treated until the disease progresses or there are too many side effects.

Phase 2

Waitlist Available

FDA Approved Drug

University of Alabama At Birmingham (+53 Sites)Clinical TrialsHoffmann-La Roche

Image of USC/Norris Comprehensive Cancer Center in Los Angeles, United States.

Phase-Based Progress Estimates

Pembrolizumabfor Urinary Bladder Cancer

This trial is testing a combination of two drugs, pembrolizumab and vorinostat, to treat advanced prostate, renal, or urothelial cell carcinoma. The primary objective is to assess the early signals for anti-tumor activity, and the secondary objectives are to evaluate the overall safety profile, select the recommended Phase 2 Dose, and characterize immune cell subsets and miRs in tumor and/or blood.

Phase 1

Waitlist Available

FDA Approved Drug

USC/Norris Comprehensive Cancer Center (+3 Sites)Roberto Pili, MD

25 Bladder Cancer Clinical Trials Near Me

Top Hospitals for Bladder Cancer Clinical Trials

Memorial Sloan Kettering Cancer Center

New York

20Active Trials

33All Time Trials for Bladder Cancer

2000First Bladder Cancer Trial

Moffitt Cancer Center

Tampa

14Active Trials

22All Time Trials for Bladder Cancer

2010First Bladder Cancer Trial

Top Cities for Bladder Cancer Clinical Trials

New York

92Active Trials

Memorial Sloan Kettering Cancer CenterTop Active Site

Los Angeles

75Active Trials

USC / Norris Comprehensive Cancer CenterTop Active Site

Bladder Cancer Clinical Trials by Phase of Trial

Phase < 1 Bladder Cancer Clinical Trials

4Active Bladder Cancer Clinical Trials

4Number of Unique Treatments

6Number of Active Locations

Magnetic Resonance Imaging 18F-fluciclovine Nephrectomy Abemaciclib

Bladder Cancer Clinical Trials 2022

Browse 200 Bladder Cancer Medical Studies Across 498 Cities29 Phase 3 Trial · 2669 Bladder Cancer Clinics

ABC123 Frameworkfor Urinary Bladder Cancer

AZD8853for Carcinoma, Non-Small-Cell Lung

Erdafitinib Intravesical Delivery Systemfor Receptors, Fibroblast Growth Factor

TARA-002for Urinary Bladder Cancer

Enfortumab Vedotinfor Urinary Bladder Cancer

Pembrolizumab/Vibostolimab Co-Formulationfor Oral Squamous Cell Carcinoma

TAR-200for Urinary Bladder Cancer

RMC-5552for Tumors, Solid

TAR-200for Urinary Bladder Cancer

TAR-200for Urinary Bladder Cancer

BT8009for Cancer of Esophagus

Fiducial Marker Placementfor Cancer

SGN-B6Afor Cancer of Stomach

Magnetic Resonance Imagingfor Urinary Bladder Cancer

Pembrolizumabfor Urinary Bladder Cancer

BT5528for Advanced Solid Tumor Identified as Positive for EphA2 Tumor Expression by Central Laboratory (Phase 1)

Erdafitinibfor Urinary Bladder Cancer

Nivolumabfor Urinary Bladder Cancer

BMS-986205for Urinary Bladder Cancer

Olaparibfor Urinary Bladder Cancer

Enfortumab Vedotin (EV)for Cancer of Ureter

Vicineumfor Urinary Bladder Cancer

Enfortumab Vedotinfor Urologic Neoplasms

Atezolizumabfor Urinary Bladder Cancer

Pembrolizumabfor Urinary Bladder Cancer

Browse 200 Bladder Cancer Medical Studies Across 498 Cities
29 Phase 3 Trial · 2669 Bladder Cancer Clinics